Glaucoma is a leading cause of preventable and irreversible blindness. Glaucoma is a chronic and progressive neurodegenerative disorder causing loss of retinal ganglion cells and their axons. Characteristic ‘cupping’ of the optic disc is seen with corresponding loss of visual field. Elevated intraocular pressure (IOP) is a causative risk factor for the development and progression of glaucoma, and lowering IOP is the mainstay of treatment. Besides IOP, other risk factors are well-known, e.g. age, family history, and race (e.g. African descent).

The balance of aqueous humor production (inflow) and drainage (outflow) determines the IOP. The pathophysiology of elevated IOP in primary open-angle glaucoma (POAG) is dysfunctional drainage, specifically through the trabecular meshwork (TM). The exact mechanisms that control drainage through the TM are not fully understood, but changes in the extracellular matrix (ECM) are one of the reasons. Furthermore, pathological accumulations of certain ECM structures within the TM have been described as causative in eyes with POAG.

In managing glaucoma patients, lowering the IOP is the only available treatment with a significant body of supporting evidence. Medical reduction of IOP is the first line of therapy in most cases. If medical treatment fails, there are several well-established surgical procedures to reduce IOP.

Trabeculectomy (TE) as it is performed today was introduced in 1968 by Cairns and at the same time by Linner. It is still the gold standard in glaucoma surgery. The aqueous flows via a scleral flap from the anterior chamber into the subconjunctival space. TE is very effective in long-term IOP reduction. The use of antimetabolites during surgery provides an even better long-term success.

The greatest outflow resistance is at the location of the juxtacanalicular TM (JCT) and inner wall of Schlemm’s canal. Schlemm’s canal communicates with the episcleral veins. The drainage of aqueous outflow through the TM into Schlemm’s canal and later on into the episcleral veins is called the trabecular outflow (83–96 %, ‘conventional’ pathway), the remaining 5–15 % of the aqueous humor is drained via the uveoscleral pathway (‘alternative’ pathway). The JCT region, which includes the inner wall of Schlemm’s canal and the underlying TM, is thought to be the region where regulation of aqueous humor outflow takes place.

Although TE remains the mainstay of surgical glaucoma treatment, it remains feasible to enhance aqueous outflow through the conventional pathway. Several surgical approaches have been tried, e.g. ab interno TE with the Trabectome™, goniotomy, and goniopuncture, which can be performed with or without endoscopy.

This paper focuses on another technique, excimer laser trabeculotomy (ELT, also known as excimer laser trabeculostomy). First, goniotomy and goniopuncture are discussed briefly.

**Abstract**

Usually an elevated drainage resistance is responsible for elevated intraocular pressure (IOP) in glaucoma, while aqueous humor production is still normal. Therefore, currently there are great efforts to develop surgical techniques that enhance the conventional outflow through the trabecular meshwork and Schlemm’s canal and into the episcleral veins. One of these techniques is excimer laser trabeculotomy (ELT). ELT is easy to perform at the end of cataract surgery. The duration of cataract surgery is only prolonged by 2–3 minutes. IOP can be reduced by up to 34.7 %. It is known that the effect of IOP reduction is constant over time, unlike argon or selective laser trabeculoplasty. The procedure is also very safe. If required later, filtering surgery is not compromised because there is no conjunctival touch during ELT and therefore no scarring of the conjunctiva is induced. For a selected cohort of glaucoma patients, this procedure may avoid the need for trabeculectomy.

**Keywords**

Glaucoma, glaucoma surgery, trabecular meshwork, phacoemulsification, excimer laser trabeculotomy, excimer laser trabeculostomy, phaco-eximer laser trabeculotomy, trabecular outflow, goniopuncture, goniotomy

**Disclosure:** The authors have no conflicts of interest to declare.

**Received:** October 15, 2011  **Accepted:** January 15, 2012  **Citation:** US Ophthalmic Review, 2012;5(1):33-6  **DOI:** 10.17925/USOR.2012.05.01.33

**Correspondence:** Jens Funk, MD, PhD, Department of Ophthalmology, University Hospital Zurich, Frauenklinikstrasse 24, 8091 Zurich, Switzerland. E: jens.funk@usz.ch

**Endoscopic Goniotomy**

Marc Töteberg-Harms, MD, Peter P Ciechanowski, MD, and Jens Funk MD, PhD

1. Research Fellow, Massachusetts Eye and Ear Infirmary, Harvard Medical School; 2. Resident, Department of Ophthalmology, University Hospital Zurich; 3. Professor, Department of Ophthalmology, University Hospital Zurich

Glaucoma

© TOUCH BRIEFINGS 2012
Glaucoma

Goniotomy

Goniotomy is used to enhance the route for aqueous humor outflow into Schlemm’s canal. For this purpose, the tissue of the chamber angle is incised under direct visualization with an operating microscope and a surgical gonioscopy lens or with a fiber optic probe. Instead of a surgical knife, a photoablative laser device can be used. In 1997, Medow and Sauer reported the first use of endoscopic goniotomy in human subjects. Goniotomy is known as the gold standard for the treatment of primary congenital (infantile) glaucoma. A successful goniotomy improves the aqueous outflow and IOP control can be maintained for extended periods of time.

Goniopuncture

Nowadays goniopuncture describes an intervention with laser following deep sclerectomy. The laser is used to create a pore in the trabecular Descemet membrane, which enables an aqueous outflow from the anterior chamber to the intrascleral reservoir. Laser goniopuncture can be performed using a neodymium:yttrium–aluminum–garnet (YAG) laser. Puncturing the trabecular Descemet membrane leads to success rates similar to those of TE.

Previously, Feltgen et al. used an erbium:YAG laser. They reported that goniopuncture in combination with cataract surgery produced an IOP reduction comparable to that of combined TE and cataract surgery. In addition, the rate of post-operative complications is low.

Excimer Laser Trabeculotomy

ELT ab interno is a minimally invasive surgical technique to reduce IOP in patients with glaucoma or ocular hypertension by creating pores from the anterior chamber into Schlemm’s canal. There are almost no thermal side effects or damage to the outer wall of Schlemm’s canal.

The punctual ablation of TM by an excimer laser was first described in 1996 by Vogel et al. They used a prototype laser and the application was monitored using a contact lens. The ELT technique differs from that of other minimally invasive glaucoma laser techniques like argon laser trabeculotomy (ALT) or selected laser trabeculotomy (SLT). The latter ones induce tissue alterations by heat or tissue remodeling, respectively. Therefore, the effects of ALT and SLT reduce over time. After ELT, the edges of the openings are found to be very smooth. This should minimize wound healing, and thus contribute to a long-lasting IOP reduction.

If filtering surgery is required following ELT, the outcome is not compromised by ELT. As there is no conjunctival touch during ELT, no conjunctival scarring that would influence the outcome of TE is expected. It is known that phacoemulsification in isolation results in reduced IOP. The IOP reduction of combined phaco and ELT (phaco-ELT) is greater than that of either cataract surgery or ELT alone. One likely explanation is the deepening of the anterior chamber angle by extraction of the thickened cataractous lens.

ELT could easily be performed at the end of a clear cornea phacoemulsification or as a stand-alone procedure. It can reduce IOP for an extended period of time and is associated with a low rate of complications. The duration of cataract surgery is only prolonged by 2–3 minutes for the ELT. The same corneal incision as for phacoemulsification is used.

In our procedure, at the end of the cataract surgery or at the beginning of a stand-alone procedure, a medical miosis is performed with acetylcholine chloride and the anterior chamber deepened with viscoelastics. An endoscopically guided photoablative laser (see Figure 1) operating at a wavelength of 308 nm (excimer laser, AIDA, TU-Laser, Munich, Germany) is used to create ten microperforations into the TM spread over an area of 90°. Each microperforation is about 0.5 mm in diameter (diameter of the laser fiber). Further details of the device are given in Table 1. To transmit the complete energy of the laser to the TM,
the laser tip must make contact with the tissue (see Figure 2). After laser application, a formation of bubbles can be seen together with a small retrograde bleeding. This indicates the perforation of the TM and the inner wall of Schlemm’s canal (see Figure 3). Bleeding stops spontaneously almost immediately. At the end of the surgical procedure, the viscoelastics are removed with aspiration and irrigation and the globe is pressurized to approximately 15 mmHg.

We conducted a preliminary study that included 28 eyes of 28 patients with a pre-operative IOP of over 21 mmHg (mean 25.33 ± 2.85 mmHg). One year after combined phaco-ELT we found a mean IOP reduction of 8.79 ± 5.28 mmHg (-37.70 %, p < 0.001). During the same period, the number of antiglaucoma medications could be reduced by an average of 0.79 ± 1.50 per patient (-21.57 %, p = 0.017). The complication rate was similar to that of normal cataract surgery and no serious complications occurred. The success rate was 64.3 % (as defined by post-operative IOP < 21 mmHg in addition to IOP reduction of ≥20 % with or without medical therapy and no further glaucoma surgery within the follow-up period).78

A larger study is ongoing. In this study, eyes with IOP less than 22 mmHg are also included. The preliminary results of 73 eyes of 64 patients with a mean age of 76.51 ± 9.36 years after a follow-up period of 12 months post-surgery are shown in Table 2.

**Table 2: Change of Pre- to Post-operative values of Intraocular Pressure and Antiglaucoma Medication**

<table>
<thead>
<tr>
<th>Area of Interest</th>
<th>ΔIOP (mmHg)</th>
<th>Percentage</th>
<th>p Value</th>
<th>ΔAGM</th>
<th>Percentage</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>All</td>
<td>-4.41 ± 6.18</td>
<td>-21.99 %</td>
<td>p&lt;0.05</td>
<td>-1.02 ± 1.47</td>
<td>-73.91 %</td>
<td>p&lt;0.05</td>
</tr>
<tr>
<td>SG 1</td>
<td>-1.40 ± 4.58</td>
<td>-8.75 %</td>
<td>p&lt;0.05</td>
<td>-1.20 ± 1.47</td>
<td>-48.58 %</td>
<td>p&lt;0.05</td>
</tr>
<tr>
<td>SG 2</td>
<td>-8.79 ± 5.27</td>
<td>-34.70 %</td>
<td>p&lt;0.05</td>
<td>-0.79 ± 1.50</td>
<td>-54.11 %</td>
<td>p&lt;0.05</td>
</tr>
</tbody>
</table>

For all study eyes and subgroup (SG) 1 with a pre-operative intraocular pressure (IOP) <22 mmHg and SG 2 with a pre-operative IOP ≥21 mmHg. AGM = antiglaucoma medication.

**Conclusion**

A range of surgical options to lower IOP is available. TE with antimetabolites is still the gold standard. The goal of minimizing post-operative complications demands minimally invasive procedures. In the event of a very low target IOP, TE is the treatment of choice. However, it may also be possible to achieve a sufficient reduction in IOP with endoscopic surgical methods. Goniotomy is mostly used in infantile glaucoma, and gonipuncture is an option following deep sclerectomy. Excimer laser trabeculotomy could become more popular in combination with phacoemulsification in minimally invasive endoscopic surgery, as it causes fewer complications compared to TE. For a selected cohort of glaucoma patients, in particular those with an IOP over 21 mmHg and at least moderate cataract, the combined procedure of ELT and phacoemulsification appears to be a promising approach to avoid (or at least to delay for some years) the onset of TE.

---